The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Subscribe To Our Newsletter & Stay Updated
